Amussen Hunsaker Associates LLC Cellectar Biosciences, Inc. Transaction History

Amussen Hunsaker Associates LLC

  • $715 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 19, 2019
SELL
$12.9 - $36.9 $12,293 - $35,165
-953 Closed
0 $0
Q3 2018

Nov 16, 2018
BUY
$21.9 - $79.0 $20,870 - $75,287
953 New
953 $2,000

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.59M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Amussen Hunsaker Associates LLC Portfolio

Follow Amussen Hunsaker Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amussen Hunsaker Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Amussen Hunsaker Associates LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email